« Back
Home /
Prexasertib

Prexasertib

Item no.	HY-18174-100mg
Manufacturer	MedChem Express
CASRN	1234015-52-1
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	98.74
Citations	bioRxiv. January 04, 2022.<br>Br J Cancer. 2021 Mar 26.<br>Cancers (Basel). 2021 Aug 20;13(16):4200.<br>Cancers. 2020 Aug 26;12(9):2426.<br>Cancers. 2020 Jun 29;12(7):1726.<br>Cell Biol Toxicol. 2021 Sep 14.<br>Cells. 2024 Apr 19;13(8):710.<br>Mol Cancer Res. 2019 Oct;17(10):2102-2114.<br>Nat Commun. 2019 Aug 2;10(1):3485.<br>Oncogene. 2022 Oct 12.<br>Patent. US20210353605A1.<br>Research Square Preprint. 2021 May.<br>Sci Rep. 2021 Feb 4;11(1):3176.<br>Thorax. 2021 Jul 5;thoraxjnl-2021-217377.<br>Universität Hamburg. Elektronische Dissertationen und Habilitationen. 2022 Aug.<br>Utrecht University. 2023 Feb.<br>bioRxiv. September 10, 2021.<br>Methods Mol Biol. 2018;1711:351-398.<br>[1]King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1<br>[2]Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483.
Smiles	NCCCOC(C=CC=C1OC)=C1C2=CC(NC3=NC=C(C#N)N=C3)=NN2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY2606368
Available
Product Description	Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of 50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	365.39
Clinical_Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 16.67 mg/mL (ultrasonic)
Manufacturers Target	Apoptosis; Checkpoint Kinase (Chk)
Isoform	Chk1; Chk2
Pathway	Apoptosis; Cell Cycle/DNA Damage

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-18174-100mg-safety-datasheet.pdf